ArticleACS omega2026
Inhalable Chitosan Microparticles: A Spray-Drying Approach for Enhanced Pulmonary Delivery of Rifampicin.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to produce spray-dried microparticles with a higher payload of rifampicin and a suitable size range for targeted drug delivery to alveolar macrophages. The microparticles were initially optimized with respect to solution feed rate, concentration of chitosan, and addition of surfactant, followed by homogenization. The optimized formulations were loaded with rifampicin in the ratios of 1:1 (F4L), 1:2 (F3L and F5L), and 1:4 (F2L), respectively. The microparticles were assessed for their particle size, morphology, drug content, flow properties, drug release, and aerodynamic performance. The chemical compatibility of the drug with excipients in microparticles was assessed using FTIR, while the crystalline and/or amorphous nature of the spray-dried powder was confirmed using XRD analysis. The pharmacokinetic parameters were compared after oral and intratracheal administration in rats. The microparticles, within the size range of 2 to 6 μm and percentage yield of 23-51%, were efficiently synthesized. The structure of the microparticles was significantly altered with increasing concentrations of rifampicin in the microparticles. The microparticles had a drug association efficiency of above 60%. The microparticles released rifampicin in a sustained fashion (>95%) by anomalous non-Fickian diffusion. The optimized microparticles (F5L) achieved a dispersed fraction of 89%, an inhaled fraction of 69% with FPF
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.